Ananda Pharma PLC has announced plans to withdraw its shares from the AQSE Growth Market and re-register as a private company, proposing to continue operations under the name Ananda Pharma
Ananda Pharma PLC has announced plans to withdraw its shares from the AQSE Growth Market and re-register as a private company, proposing to continue operations under the name Ananda Pharma
Ananda Pharma PLC has announced plans to withdraw from the AQSE Growth Market and re-register as a private company, citing the high cost of being publicly listed, regulatory complexity and
Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, is pleased to announce that the post annual report corporate
Directorship Changes
In the last few years, it has become increasingly evident that medicinal cannabis is not only revolutionising the way we manage specific health issues, it’s also quietly transforming the economic
Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines, announces that further to the 6 June 2025 announcement, it
Shares in Celadon Pharmaceuticals PLC (AIM: CEL), a UK-based pharmaceutical company specialising in cannabis-based medicines, surged over 25% in early trading following a financial update.
Ananda Pharma plc (AQSE: ANA), a UK company focused on the development of cannabinoid therapies targeting the treatment of complex, chronic inflammatory pain conditions is pleased to announce the appointment of Andy Rust as
Finance Director Jeremy Sturgess-Smith introduces Ananda Developments, outlining the company’s mission, strategic focus, and what makes it distinct within the CBD and drug development sectors.
Shares in Celadon Pharmaceuticals PLC (AIM: CEL) plummeted 50% in early trading due to delays in accessing £1.3 million of funding.
On Monday, Germany legalized recreational cannabis use, marking it the largest EU nation to do so, amidst strong opposition from some politicians and medical groups.
The illegal cannabis market in Britain, estimated at £2.6 billion annually, poses a significant challenge for authorities amidst growing interest in its use for pain relief.